PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites. It is planned to determine the safety and efficacy of intraperitoneal infusion of PD-1 inhibitor combination with PRaG therapy.
Epistemonikos ID: 70742fa9a7137dbee5d82efe2fb7c790045b5926
First added on: May 13, 2024